The Committee has agreed to examine general issues regarding the approval process for newly licensed medicines and the system of Individual Patient Treatment Requests (IPTRs).
Committee has agreed that once the Scottish Government commissioned review of
access to new medicines has published it
will hold an oral evidence session.
This oral evidence session will likely to be with the Cabinet Secretary for Health and
Wellbeing, Professor Philip Routledge, Professor Charles Swainson and the
Chief Pharmaceutical Officer Professor Bill Scott.
The provisional date for
this meeting is Tuesday 7 May.
The Committee has received written submissions in relation to access to new medicines.
Read the written submissions received
The Committee conducted an oral evidence session on 18 September with representatives from the following organisations:
- Scottish Medicines Consortium
- Association of British Pharmaceutical Industry
- Royal College of Physicians (Consultants)
- NHS Boards
Official Report of Meeting 18 September 2012 (498KB pdf)
On 6 November the Committee agreed to hold two further evidence sessions on access to new medicines. The first of these was on Tuesday 4 December and focused on access to cancer drug treatments.
The Committee conducted an oral evidence session on 4 December with representatives from the following organisations:
Scottish Cancer Research Network (West of Scotland)
Scottish Cancer Research Network (South East Scotland)
- Scottish Cancer Research Network (East of Scotland)
- Scottish Melanoma Group
- Beatson West of Scotland Cancer Centre
- Cancer Research UK
James Whale Fund for Kidney Cancer
- Macmillan Cancer Support
- Myeloma UK
- Melanoma Action and Support Scotland
- Prostate Cancer UK
Letter from Cabinet Secretary to the Convener, 14 January 2013 (97KB pdf).
Scottish Government News Release 14 January 2013.
Letter from Cabinet Secretary to the Convener of Public Petitions Committee 30 January 2013 (111KB pdf).
Official Report of Meeting 4 December 2012 (573KB pdf)
The second was on 29 January. This will took a similar form to the meeting on 4 December, but focused on other conditions.
The Committee conducted an oral evidence session on 29 January with representatives from the following organisations:
- British Heart Foundation
- Newcastle University
- Alliance Scotland, (the ALLIANCE)
- Rare Disease UK
- PNH Scotland, PNH Alliance
- Salford Royal NHS Foundation Trust
- Association for Glycogen Storage Disease (UK)
- Ivacaftor Patient Interest Group
Official Report of Meeting 29 January 2013 (384KB pdf)
Following these sessions, the Committee will review the evidence it has taken and consider how to conclude this work.